For relief of canine allergic itch
Recommend Apoquel first-line for the fast
relief loved by itchy dogs
For helpful resources to support your practice and patients, visit Apoquel.com
APOQUEL AND APOQUEL CHEWABLE INDICATIONS: Control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs
at least 12 months of age.
APOQUEL AND APOQUEL CHEWABLE IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12
months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and
may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a
history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval.
Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions
such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and
diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines.
See full Prescribing Information at http://www.apoqueltabletandchewablepi.com
References: 1. Gadeyne C, Little P, King VL, et al. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic
dermatitis in client-owned dogs in Australia. Vet Dermatol. 2014;25(6):512-e86. 2. Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and
associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479-e114. 3. Cosgrove SB, Wren JA, Cleaver DM, et al. A blinded, randomized, placebo-controlled
trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (APOQUEL®) in client-owned dogs with atopic dermatitis. Vet Dermatol. 2013;24(6):587-e142. 4. Data on file, Study
Report No. A162R-US-21-C32, 2022, Zoetis Inc. 5. Visser M, Walsh K, King V, et al. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and
atopic dermatitis. BMC Vet Res. 2022;18(1):103. doi:10.1186/s12917-022-03210-x
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted.
© 2025 Zoetis Services LLC. All rights reserved. APQ-01634R2
Canine-approved
• 91.6% of dogs
voluntarily accepted
Apoquel Chewable
twice a day for 7 days
5
Now available in convenient
100-count blister packs
The first and only chewable dosing
option for canine allergic itch
Like Apoquel tablets, Apoquel Chewable can be taken
with or without food*
(oclacitinib
chewable
tablet)
Chewable
Visit Covetrus.vet/Apoquel
